The drug will be produced at the group’s formulations manufacturing facility in Ahmedabad
Zydus Cadila has received approval from the US health regulator to market its anti-hypertensive olmesartan medoxomil tablets in the US market.
The company has received “final approval from the United States Food and Drug Administration (US FDA) to market olmesartan medoxomil tablets in the strengths of 5 mg, 20 mg and 40 mg,” Cadila Healthcare said in a filing to BSE.
The drug is an anti-hypertensive and will be produced at the group’s formulations manufacturing facility in Ahmedabad, it added.
As per IMS MAT February 2017, the estimated sales for olmesartan is $982 million, Cadila Healthcare said. The group currently has over 110 approvals and has so far filed 300 abbreviated new drug applications (ANDA)s, it added.